The untested legal theory behind Trump's Medicaid payment pauses

The legal hook for the Trump administration’s Medicaid payment pauses is real. CMS can point to 42 CFR § 430.40, which allows the agency to defer payment of a state’s Medicaid claim when it has reason to question whether the claim is allowable, while it asks for more information and decides whether the claim should be paid, reduced, or disallowed.[1] That matters. A payment pause without any regulatory basis would be an easier case.

But § 430.40 is not the only payment-control rule in the Medicaid regulations, and it is not the one that carries the heavier procedural protections. Section 430.35 governs withholding when CMS finds that a state plan no longer complies with federal requirements; that path requires reasonable notice and an opportunity for a hearing before payments are withheld.[2] Disallowance is different again: it is a post-payment denial of federal financial participation, with Departmental Appeals Board review rights.[3]

That distinction is where the legal authority question actually begins. Deferral is built for skepticism about claims. Withholding is built for a more consequential judgment about state compliance. Disallowance is built for the fight after money has already been claimed or paid. When CMS uses a deferral to pause hundreds of millions of dollars before any hearing, the question is not whether the word “defer” appears in the regulations. It does. The question is whether a no-hearing mechanism is being asked to do work that the hearing-based mechanism was designed to handle.

The clean distinction between deferral, withholding, and disallowance

In ordinary Medicaid finance, these tools sit at different points in the federal-state payment relationship. A deferral pauses payment while CMS develops the record. It is temporary on paper, and the regulation does not state a dollar cap.[1] A withholding follows a more formal route: CMS must give notice and a chance for hearing before it cuts off federal financial participation because of a state-plan compliance problem.[2] A disallowance, by contrast, is a denial of federal participation in an expenditure, generally after the state has made the claim, with appeal rights through the Departmental Appeals Board.[3]

Those procedural differences are not decoration. Medicaid is not a grant program where the federal government simply pays a bill and later chats about conditions. States budget around expected federal financial participation. Providers build payroll, staffing, and service capacity around state payment systems. A pause at the federal level can become an operational problem well before a court decides whether the pause was lawful.

That is why the current dispute cannot be answered by reciting § 430.40 alone. The administration has statutory and regulatory language to cite for deferrals. It has not yet supplied a settled answer to the harder question: whether the size and use of these deferrals fit within the traditional limits of federal Medicaid payment control.

Minnesota made the theory visible

The first major move came on February 25, 2026, when CMS announced that it was deferring $259 million in federal Medicaid payments to Minnesota as part of the administration’s CRUSH initiative, with the announcement tied to a White House press conference by Vice President Vance.[4] In April 2026, CMS deferred an additional $91 million from Minnesota.[5]

The administration framed the action in fraud-control terms. Fraud review is a legitimate federal interest; Medicaid program integrity is not optional. But the legal concern is the fit between the stated concern and the procedural vehicle selected. A claim-level deferral asks whether particular claims can be supported. A broad pause tied to public fraud messaging begins to look less like a narrow audit hold and more like a financing sanction imposed before the hearing machinery has run.

Minnesota’s challenge forced that distinction into court quickly, but only partially. The state sought to block the deferral, arguing among other things that the federal government was using payment authority in a way that violated constitutional limits on federal spending conditions. The court did not decide the merits of that broader theory.

California turned the size problem into the main problem

California then gave the dispute its scale. In May 2026, CMS deferred $1.133 billion from California, targeting In-Home Supportive Services home-care spending.[6] Georgetown’s Center for Children and Families described the California action as combining routine administrative deferrals with a much larger program-wide deferral, and attributed 44% of the total to growth analysis and 56% to program-integrity metrics involving statistical outliers.[7]

That methodology matters because it moves the center of gravity away from the familiar question, “Can the state document these claims?” and toward a more general suspicion: spending increased, patterns look unusual, therefore payment can be paused while the state explains. Statistical signals can justify scrutiny. They do not, by themselves, answer whether a deferral of that size remains the same regulatory act Congress and CMS have traditionally treated as a temporary claim-resolution tool.

KFF described CMS’s approach in these disputes as a new one, focused on spending growth and statistical outliers rather than individualized claim-level findings.[5] That is a careful formulation. It does not prove that CMS has found fraud. It says CMS is using indicators to justify further review. The legal importance is in the distance between indicator and consequence: a signal that warrants questions is now being paired with a pause large enough to alter state financing.

The July round joined deferral and withholding in the same dispute

The July 21, 2026 actions are the point at which the dispute stops looking like a set of isolated claim holds. HHS announced new deferrals of $867.5 million from California and $199 million from Minnesota for fraud review.[8] Including the earlier Minnesota and California actions, the total deferrals across the two states reached approximately $1.75 billion.

At the same time, CMS had sent Minnesota a proposed withholding notice of $515 million per quarter under § 430.35.[5] That is not just another large number. It is the use of both payment-control tracks against the same state in a fraud-framed dispute: a deferral route that does not require a hearing before the pause, and a withholding route that does.

KFF and the Bipartisan Policy Center both identified the simultaneous use of deferral and withholding in this context as unprecedented in Medicaid’s 60-year history.[3][9] The point is not that unprecedented automatically means unlawful. Agencies sometimes confront new facts with old tools. But when the old tool chosen first is the one with fewer procedural demands, novelty becomes legally relevant.

The comparison with prior withholdings is stark. Earlier withholding actions involving Texas in 2019, Alabama in 2017, Arkansas in 2016, Florida in 2014, and Missouri in 2010 were applied at 1% to 10% of the federal share for administrative costs of specific services.[3][9] Minnesota’s proposed withholding was described as roughly 20% of the state’s total federal share, a different order of consequence from a targeted administrative-cost sanction.[9]

This is where fraud rhetoric does the least legal work. If CMS has evidence that particular claims are unsupported, inflated, or otherwise unallowable, the Medicaid rules give it tools. If CMS believes a state is operating its program out of compliance with federal requirements, the regulations give it a withholding process. The unresolved issue is whether CMS may use deferral at a scale that functionally pressures state compliance before the state receives the hearing that withholding would require.

Minnesota v. Oz answered only the first procedural challenge

The first court ruling did not bless the entire enforcement theory. In Minnesota v. Oz, the District of Minnesota denied a preliminary injunction on April 6, 2026, and the holdings that matter are narrower than the political reaction to the case.[10]

• The court treated the deferral as non-final agency action, which meant APA review was not available at that stage.[10]
• The court rejected Minnesota’s Fifth Amendment due process theory because a state is not a “person” for that purpose.[10]
• The court found no regulatory cap on the amount CMS may defer under § 430.40.[10]
• The court concluded that public statements by Vice President Vance and CMS Administrator Oz did not make the strong showing of bad faith or clear constitutional violation needed to justify preliminary relief.[10][11]

Those holdings are significant. They mean Minnesota could not stop the initial deferral merely by arguing that the amount was too large, that the politics looked suspect, or that the state was entitled to ordinary due process as a constitutional person. They also confirm an important textual point: § 430.40 does not contain an express dollar ceiling.

But that is not the same as deciding that CMS can use deferral as a substitute for withholding whenever the agency wants immediate leverage. A preliminary injunction ruling is not a merits judgment. The court did not resolve the Spending Clause theory, the anti-commandeering theory, or the ultimate scope-of-authority question.[10] It left the hardest issue for later.

The Spending Clause question is still waiting

Minnesota’s complaint raised Spending Clause arguments grounded in the Pennhurst principle that federal conditions on state receipt of funds must be unambiguous, along with anti-commandeering arguments.[12][13] Those claims matter because Medicaid is a cooperative federal-state program. The federal government can attach conditions to funds, but it cannot spring materially different consequences on states after they have organized their programs and budgets around the statutory bargain.

The administration’s strongest answer is textual: § 430.40 says CMS may defer claims it questions, and the rule does not cap the amount.[1] That is a real answer to a facial-authority challenge. A state that submits claims for federal financial participation is on notice that CMS may question allowability and temporarily withhold payment while it reviews supporting information.

The state-side answer is functional: at some point, a deferral may stop operating like a temporary claim inquiry and start operating like a system-wide penalty or coerced compliance device. The regulation’s silence on a cap does not necessarily settle whether a billion-dollar freeze, announced as part of a fraud crackdown and paired with proposed withholding, remains within the Spending Clause bargain states accepted.

That is not an argument that CMS must pay every questionable claim first and ask questions later. It is an argument about procedural substitution. If the agency’s real theory is that a state’s program administration is so deficient that major federal payment streams should be cut off, § 430.35 supplies a process with notice and hearing.[2] Choosing § 430.40 first may be lawful for claim review. It is more vulnerable when the deferral is doing the practical work of withholding before the withholding process has justified itself.

Fraud claims do not erase the procedure problem

There is a temptation in these disputes to treat fraud allegations as a trump card. That is a mistake in both directions. Fraud review is a core program-integrity function, and CMS does not need to ignore statistical anomalies or spending growth. At the same time, fraud language does not convert every broad payment pause into an ordinary claim-level deferral.

KFF’s description of the new approach is useful precisely because it separates suspicion from proof: CMS is relying on statistical outliers and spending growth to support potential-fraud review, not on a completed individualized finding that every paused dollar is unallowable.[5] Georgetown’s account of the California deferral similarly describes a mix of growth analysis and program-integrity metrics, not a final adjudication of fraud.[7]

That distinction affects who bears the interim risk. If CMS later validates the claims, the state may eventually receive the money. But the pause itself lands earlier, on state Medicaid officials trying to manage cash flow, on providers waiting for predictable payment cycles, and on beneficiaries whose access can be affected when the financing system tightens. The Bipartisan Policy Center noted that the dual-tool approach has drawn attention in part because of its potential financial impact on the state and possible reductions in care access.[3]

What is settled, and what is not

A few propositions are now reasonably clear. CMS has an express regulatory basis to defer Medicaid claims it questions. The regulation does not state a dollar cap. The first federal court to consider Minnesota’s challenge did not treat the deferral as final agency action, did not accept the state’s due process theory, and did not find enough evidence of bad faith to stop the deferral at the preliminary stage.[1][10]

The unsettled proposition is the one that matters most here: whether CMS can use a no-hearing deferral mechanism at this scale, in tandem with proposed withholding, without crossing the constitutional line that governs federal conditions on state Medicaid funding.

As of July 22, 2026, the July 21 deferrals are too recent for a developed court record on that specific round. California has not yet filed a lawsuit over its deferrals. Minnesota’s first ruling is a procedural loss for the state, not a full validation of the administration’s theory. The government has shown where the regulatory authority begins. It has not yet had to prove where that authority ends.

References

1. 42 CFR § 430.40, Cornell Legal Information Institute.
2. 42 CFR § 430.35, Cornell Legal Information Institute.
3. Medicaid Payment Deferrals: What They Are and How They Work, Bipartisan Policy Center, 2026.
4. Trump Administration Prioritizes Affordability, Announcing Major Crackdown on Health Care Fraud, Centers for Medicare & Medicaid Services, February 25, 2026.
5. CMS’ New Approach to Federal Medicaid Spending in Cases of Potential Fraud, KFF, May 2026.
6. Trump Medicaid fraud freeze California, CalMatters, May 2026.
7. CMS Weaponizes Fraud Against Medicaid in California, Georgetown University Center for Children and Families, May 15, 2026.
8. HHS Defers Medicaid Payments to California, Minnesota for Fraud Review, U.S. Department of Health and Human Services, July 21, 2026.
9. What to Know About Recent Federal Actions Involving State Medicaid Program Integrity, KFF, June 2026.
10. Federal Court Upholds CMS Medicaid Funding Deferral: Key Takeaways, Snell & Wilmer.
11. Judge refuses to block Trump’s $243 million Medicaid deferral in Minnesota, Courthouse News.
12. Minnesota sues to block Trump administration’s withholding of $243 million in Medicaid funds, PBS News.
13. Minnesota sues Trump administration over Medicaid freeze, Roll Call, March 3, 2026.